If you do talk to the main person in charge, you could mention the importance of research using Gal3 inhibitors and preclinical success in halting fibrosis. They need to tie the test to that aspect of Gal3 and that will make it an easy sell. Basically the fact that Gal3 is a mediator of fibrosis and can be targeted with success.
Sentiment: Strong Buy
If that was the case they would not bother with RS and staying listed on Nasdaq, but just delist and take SP down to minimum. It's in everyone's best interest to see high SP Insiders and retail. Patience will be rewarded IMHO.
Sentiment: Strong Buy
I believe you're correct. Why else would they be converting to common. It would be stupid unless they knew something. Wink, wink.
Is there any proof that Abbott said they were going to issue PR. I talked to Abbott IR long before the launch and the never said that.
Helpful information. One significant question remains though. Since January
2015 Abbott media relations continued to verify that they were going to issue a
press release upon completion of the price/contract negotiations between
themselves and BGMD. Then Abbott, without any explanation, reversed their
intention and did not issue any Abbott press release. If Abbott is attempting to
feature and promote Gal-3 automated assay why no press release?? Abbott
rarely fails to promote their products especially after repeatedly confirming that
they would do so.
For big payday, when they complete their games, which might be soon if not now...then good news of sales will come and they will be rewarded.
Who else would be rewarded along with them? Answer: Longs
So a couple of disclaimers... I am in the business and have been at this show for over 15 years. BGMD did not, nor would there be a need for them to have a booth at this show. The important thing to understand now is that this is all about keeping BGMD going with enough cash flow while Abbott markets the test. The direct quote from one of the booth reps at Abbott was "the Galectin III assay is one of our featured products here at the show". That is a great sign to hear that they were putting the focus on the product. Most likely as Abbott continues to market this assay they will use a form of rep typically denoted as a "Cardiac Specialist" or some other designation, and this person will work with key PhD's in the market to gain adoption at major institutions, use the Top 20 Hospitals in America as a target list to start. Once this gets going and gets some recognition behind it, it will garner more support in the market. What BGMD needs is a home run with a group like Geisinger or Kaiser, or some solid IDN type system with a record of outcomes based data and how they use the test. The ramp up for volume of revenue on this test will most likely take a few years to hit its stride. I would estimate that this year (2015), likely test volumes sold into the market will be ~50,000 "new tests" this is with a full assumption that they will see complete cannibalization of their existing business in the market with a move to automated testing. Next year, with a full run rate at many of the early adopters as well as growth in the market, I would be surprised to see anything less than an incremental 250k to 500k tests sold into the market. From that point in 2017 I would expect over 1m new tests added to the existing base. And these are conservative estimates in my opinion. If they get the right people behind it from a KOL standpoint it will take off. Again, we know that everyone has opinions.... but how many were ever in the business and are selling the products?
Sentiment: Strong Buy
Thanks for that update.. Were many people taking a interest in the assay? Did Abbott people seem excited or was it just one of many products they had displayed? Anyone from BGMD in the booth? Thank's for you're observations as this is probably a lot lot lot lot more info than Bgmd will let we investors know about how things went at the meeting and where things are going...
At this point I don't know what else to think. I have never saw this kind of manipulation and
a company just turn a blind eye to it. Plus you factor in the way they keep investors in the dark
giving little to no news or only what has to be posted by law at the last min or at a time when
it will have very little impact on PPS. You watch NASDAQ compliance will not happen. Watch
this tumble after that and watch how people panic sell. They buy back the company at a discount.
They cut the share count down now they will cut the PPS down by doing nothing. This is Biotrash greed pure and simple.
Staying consistent of not helping the shareholders, that PR about compliance, assuming it comes, will likely hit on Friday after the closing bell. If that happens, your suspicion might prove to be accurate. Either way. ER is coming soon and one can hope we get answers then.
My shares were washed out and now they let them drop. My feeling is a BO is not going to happen
but they want to buyback the company and I think they are doing what they can to get it cheap. Just
look at the poor planning behind PR's that should have boosted PPS. I think a mouse fart has more pop
to it than that launch PR we had. What a big deal that was and how about that big fuss Abbott has
made over the automated test now up for sale??? BG cut sales staff so who is pushing the test? How
is it being marketed? How many shows did BG attend and speak at? For such a big deal nothing much
is said about this test. Even at near lows the stock had little buy volume. Manipulation is easy with this
volume. Even if we get good news from the NASDAQ listing how much of a pop will that give us? 20%
maybe? Huh looks like we lost that the past two trading days and I am sure more by the end of today...
they should be class action sued for this theft. Big Grifting Misrepresenting Deception. Get a NY ambulance chasing law firm on this
Well they washed the share count down and now they are taking the stock lower by manipulation.
That is how you go privet on the cheap...
AACC (the meeting in Atlanta) is the biggest trade show in the US (and I believe in the world) for Laboratory Diagnostic manufacturers. It is stunning to see the drop in price. I walked the floor yesterday at the show (35k to 40k attendees), and at the Abbott booth, the Galectin III assay was prominently discussed at the IA analyzers. I also questioned a number of booth members and they were all familiar with the assay and prepared to bring me to someone more competent in discussing the assay. There is no podium to present. Posters and papers are hung in a separate area of the show and attendees can visit the poster at specified times when the author will defend their data / results.
Sentiment: Strong Buy